Search
for
Sort by
Research
30-60 / 1000+ resultsresearch Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
research Repurposing of Linagliptin Similar FDA Approved Drugs as Antidiabetic Agents
Pranlukast and mirabegron may work as new diabetes drugs.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells
Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
research 44180 Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
research Empagliflozin targeting STAT3/Akt/Nrf2 axis promoting diabetic wound healing in rat model
Empagliflozin helps heal diabetic wounds in rats by reducing inflammation and oxidative stress.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research The Clinical Center’s Blood Glucose Management Service
The Blood Glucose Management Service improved patient safety and outcomes in managing blood sugar in hospitalized patients.
research NEW PROPRIETARY BRANDS: Cefaclor monohydrate
Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
research Investigation of the Cognitive Activity Between the Leaf Extracts of Eclipta alba and Ziziphus jujuba in Diabetic Animal Models
Ziziphus jujuba and Eclipta alba leaf extracts improve blood sugar levels and cognitive function in diabetic rats.
research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
research Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Actos, slings, finasteride, and the vaccine compensation solution.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.
research The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus
research Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
research 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
Upadacitinib effectively treats pyoderma gangrenosum.
research Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Update: baricitinib for alopecia areata
Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
research EFFECTS OF LIRAGLUTIDE ON VISCERAL ADIPOSITY INDEX IN WOMAN OF REPRODUCTIVE AGE WITH PREDIABETES
Liraglutide with metformin reduces body fat and improves blood sugar control better than metformin and inositol in women with prediabetes.
research JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib
Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
research JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
research USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
research Diabetex: A novel approach for diabetic wound healing
Diabetex improves diabetic wound healing better than metformin.